Mirxes Raises 90M to Expand Cancer Early Detection Globally
Mirxes secured over HKD 700 million in financing eight months after its IPO, with a placement price nearly 40% above the issue price, demonstrating investor confidence in its early screening technology. The funds will be used for R&D, commercialization, and global expansion. As a leading early screening company in Asia, Mirxes boasts a diverse product pipeline and AI partnerships, positioning it for further breakthroughs in precision medicine. Amidst tightening IPO regulations in Hong Kong, its compliance and growth potential make it a scarce and valuable asset.
